CBER

Prasad
Favicon Fierce Biotech

CBER Director Vinay Prasad to depart FDA—again

Prasad has drawn increased criticism throughout his tenure, especially from the rare disease community.
Darren Incorvaia Mar 6, 2026 5:30pm
Albert Bourla Pfizer CEO Bourla

Pfizer CEO Albert Bourla levels criticism of CBER's Vinay Prasad

Mar 3, 2026 4:58pm
Autoimmune CAR-TNavigating the FDAs new regulatory playbook

Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook

Feb 27, 2026 7:45am
FDA

FDA signs off on 1st gene therapy for rare genetic disease

Dec 10, 2025 12:09pm
Vinay Prasad

FDA's Prasad plans to get tougher on vaccine regulation: memo

Dec 1, 2025 11:25am
Marks
Favicon Fierce Biotech

Former FDA official Peter Marks joins Eli Lilly

Oct 7, 2025 3:49pm